TO THE EDITOR: To assess treatment response of bone metastases in breast cancer by
PET/CT, Dr. Azad et al. recently compared the change in Ki (18F-fluoride metabolic flux to …

REPLY: We thank Laffon and Marthan for their interest in our study (1). They discuss the
influence of measurement uncertainty on the ability to detect changes in measurements. We …

Our purpose was to establish whether noninvasive measurement of changes in 18F-fluoride
metabolic flux to bone mineral (Ki) by PET/CT can provide incremental value in response …

Purpose: To establish whether non-invasive measurement of changes in 18 F-fluoride
metabolic flux to bone mineral (Ki) by positron emission tomography/computed tomography …

In this issue of The Journal of Nuclear Medicine, Azad et al. compare quantitation of the
response of breast cancer bone metastases to therapy via SUV versus metabolic flux (Ki or …

TO THE EDITOR: The recent interesting and highly relevant article by Brockenbrough et
al.(1) includes a significant methodologic misconception and mistake regarding PET …

TO THE EDITOR: In the September issue of The Journal of Nuclear Medicine, Kramer et al.
comprehensively investigated the repeatability (R) of various quantitative 18F-FDG uptake …

415 Objectives Bony lesions are common sites of breast cancer metastasis, but they can be
difficult to assess for response to therapy with conventional imaging (CT and bone scan) …

TO THE EDITOR: In the September issue of The Journal of Nuclear Medicine, Kramer et al.
comprehensively investigated the repeatability (R) of various quantitative 18F-FDG uptake …

1369 Objectives: Standard measures of response such as RECIST are ineffective for bone
lesions making breast cancer patients with bone metastases ineligible for clinical trials with …